查看購物車
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1985586

標靶定序市場：依產品類型、平台、最終用戶和應用分類－2026-2032年全球市場預測

Targeted Sequencing Market by Product Type, Platform, End User, Application - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 196 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，標靶定序市場價值將達到 91.8 億美元，到 2026 年將成長至 111 億美元，到 2032 年將達到 349.7 億美元，年複合成長率為 21.04%。

主要市場統計數據
基準年 2025 91.8億美元
預計年份：2026年 111億美元
預測年份 2032 349.7億美元
複合年成長率 (%) 21.04%

對目標序列進行簡明策略展望，重點在於技術整合、臨床效用以及對決策者的營運影響。

在化學、儀器和數據分析技術的進步推動下，標靶定序已從一項小眾實驗室技術發展成為精準研究和臨床工作流程的基礎。本執行摘要整合了技術發展、應用趨勢、監管趨勢和競爭格局的關鍵進展，旨在幫助研究機構、診斷檢查室和生命科學公司的管理人員制定策略重點和投資決策。

化學技術的進步、擴充性的儀器架構以及日益成熟的生物資訊學如何重新定義整個標靶定序工作流程中的臨床和研究效用。

近年來，標靶定序解決方案的開發、部署和商業化方式發生了翻天覆地的變化。首先，化學和樣品製備的創新縮短了周轉時間，提高了標靶效率，使診斷檢查室能夠提供更快、更可靠的結果。伴隨這些技術進步，一種可擴展的儀器架構已經建立，涵蓋了從分散式實驗室的桌上型系統到分散式檢查定序中心的高通量平台，從而拓展了其應用範圍，從單例患者診斷擴展到大規模隊列研究。

2025 年關稅調整如何促進供應鏈韌性、在地化投資以及整個目標序列生態系統策略採購政策的轉變。

美國2025年實施的關稅調整的累積影響，已在目標序列的整個價值鏈中造成了明顯的摩擦，影響了籌資策略、定價趨勢和供應連續性。關稅相關的成本壓力對資本設備和耗材均造成了衝擊，推高了進口到美國的設備和試劑的到貨成本。因此，供應商和最終用戶正在修訂其採購計劃，並加快供應商多元化，以維持營運預算和專案進度。

將產品架構、平台選擇、最終用戶優先順序和應用需求與策略決策流程連結起來的基於詳細細分的洞察。

細分市場分析揭示了清晰的技術架構、用戶需求和商業性壓力，這些資訊應指南產品組合和市場進入策略。根據產品類型，市場可分為三大類：儀器、試劑和試劑盒以及軟體和服務。儀器包括適用於分散式低通量檢測的桌上型定序儀，以及專為中心檢查室和大規模研究設計的高通量定序儀。試劑和試劑盒包括基於擴增子、基於雜合反應和分子反轉探針的各種形式，每種形式都針對不同的標靶範圍、樣本類型和靈敏度要求進行了最佳化。軟體和服務涵蓋生物資訊服務和數據分析軟體，反映了對結果解讀、流程檢驗和法規遵循報告日益成長的需求。

影響美洲、歐洲、中東和非洲以及亞太地區招募和商業化的相對區域趨勢和策略挑戰。

區域趨勢差異顯著，影響美洲、歐洲、中東和非洲以及亞太地區的技術採納、監管策略和夥伴關係模式。在美洲，對診斷基礎設施和大規模臨床研究基地的投資正在推動高通量平台和整合生物資訊解決方案的快速普及，這些方案支援轉化研究和集中式檢測網路。該地區的相關人員優先考慮與當地監管機構的監管協調、臨床檢驗和證據生成，以支持臨床應用和支付方參與。

儀器、試劑和生物資訊學的專業知識，結合夥伴關係和服務模式，如何決定永續的競爭地位。

企業層面的趨勢反映了競爭格局中專業化、整合和服務差異化正在決定企業定位。專注於儀器創新的供應商強調通量、自動化和「從樣本到結果」的工作流程，以減少人工操作並實現分散式檢查。同時，試劑和試劑盒供應商則專注於檢測的穩健性、批間一致性以及與多個平台的易於整合，以最大限度地滿足其目標應用場景。

領導者可採取的策略重點，以增強互通性、監管合應對力、供應鏈韌性和實證商業化。

產業領導者應協調一系列策略行動，以增強韌性、加速產品普及並抓住更高附加價值的機會。首先，應優先考慮跨平台的互通性和開放標準，使客戶能夠以最小的阻力整合儀器、試劑和分析功能。這將降低買家的抵觸情緒，並擴大目標用戶群。其次，應在產品生命週期的早期階段投資於法規遵循和臨床證據能力，以縮短產品投入臨床實用化的時間，並為保險報銷談判提供支援。

混合研究框架結合了相關人員訪談、技術文獻整合和監管審查，以確保獲得與背景相關的、可操作的見解。

本研究利用結構化訪談、技術檢驗審查和跨區域政策分析，整合一手和二手資訊，對靶向測序趨勢進行全面評估。研究人員對檢查室管理人員、檢測開發人員、採購經理和監管專家進行了初步的定性訪談，以了解營運挑戰、應用促進因素和證據產生策略。這些對話有助於解讀不同平台架構之間的技術權衡，並為商業化和產品開發提供指導指南。

將策略挑戰和操作指南相結合，以將標靶定序的進展轉化為永續的臨床和商業性影響。

總之，標靶定序技術處於技術能力和臨床需求的策略性交會點，能夠提供精準的基因組分析，從而支持診斷、治療和公共衛生領域的應用。化學、儀器和生物資訊學的進步正在拓展這項技術的效用，並推動將檢測方法與整合分析能力相結合的新型經營模式的出現。同時，監管預期、支付方審查和貿易政策等外部因素正在影響產品從研發到常規應用的轉變。

目錄

第1章：序言

第2章：調查方法

  • 調查設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查的前提
  • 研究限制

第3章執行摘要

  • 首席主管觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 市場進入策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會映射
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 標靶定序市場：依產品類型分類

  • 裝置
    • 桌上型音序器
    • 高通量定序儀
  • 試劑和試劑盒
    • 基於擴增子的試劑盒
    • 雜合反應基礎試劑盒
    • 基於MIP的試劑盒
  • 軟體服務
    • 生物資訊服務
    • 數據分析軟體

第9章 標靶定序市場：依平台分類

  • 擴增子序列
    • 多重PCR
    • 基於UMI的定序
  • 混合捕獲
    • 基於誘餌的捕獲
    • 基於探針的捕獲
  • 分子反轉探針
    • 用於 CNV 分析的 MIP 探針
    • 用於SNP檢測的MIP探針

第10章 標靶定序市場：依最終用戶分類

  • 學術和研究機構
  • 醫院和診斷中心
    • 即時檢驗檢查室
    • 參考實驗室
  • 製藥和生物技術公司
    • 臨床研究機構
    • 藥物發現部門

第11章 標靶定序市場：按應用領域分類

  • 生物標記發現
    • 藥物基因體學學生物標記
    • 預測性生物標記
  • 遺傳性疾病
    • 產前檢查
    • 罕見疾病的診斷
  • 感染疾病
    • 抗生素抗藥性檢測
    • 病原體檢測
  • 腫瘤學
    • 診斷
    • 預後診斷
    • 治療診斷學

第12章 標靶定序市場：按地區分類

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第13章 標靶定序市場：依組別分類

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第14章 標靶定序市場：依國家分類

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

第15章：美國標靶定序市場

第16章：中國標靶定序市場

第17章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • 10x Genomics, Inc.
  • A-Alpha Bio, Inc.
  • Agilent Technologies, Inc.
  • Azenta Life Sciences
  • BGI Genomics Co., Ltd.
  • Bio-Rad Laboratories, Inc.
  • CD Genomics
  • DH Life Sciences, LLC
  • Element Biosciences
  • F. Hoffmann-La Roche Ltd.
  • Illumina, Inc.
  • LGC Limited
  • Macrogen, Inc.
  • MGI Tech Co., Ltd.
  • Oxford Nanopore Technologies PLC
  • Pacific Biosciences of California, Inc.
  • Paragon Genomics, Inc.
  • PerkinElmer, Inc.
  • Psomagen, Inc.
  • QIAGEN NV
  • Singular Genomics Systems, Inc.
  • Takara Bio Inc.
  • Tecan Trading AG
  • Thermo Fisher Scientific Inc.
  • Twist Bioscience Corporation
Product Code: MRR-1E2F1ED7E6A7

The Targeted Sequencing Market was valued at USD 9.18 billion in 2025 and is projected to grow to USD 11.10 billion in 2026, with a CAGR of 21.04%, reaching USD 34.97 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 9.18 billion
Estimated Year [2026] USD 11.10 billion
Forecast Year [2032] USD 34.97 billion
CAGR (%) 21.04%

A concise strategic orientation to targeted sequencing highlighting technological integration, clinical utility, and operational implications for decision-makers

Targeted sequencing has evolved from a niche laboratory technique into a cornerstone of precision research and clinical workflows, driven by advances in chemistry, instrumentation, and data analytics. This executive summary synthesizes critical developments across technology, adoption patterns, regulatory dynamics, and competitive activity to support senior leaders in research organizations, diagnostics laboratories, and life sciences companies as they weigh strategic priorities and investment decisions.

The narrative that follows positions targeted sequencing within a broader genomics ecosystem where sample throughput, assay specificity, and bioinformatics sophistication now determine commercial and clinical differentiation. Key drivers include the demand for focused genomic interrogation in oncology, inherited disease diagnostics, and infectious disease surveillance, as well as the need for cost-efficient, high-confidence variant detection in routine workflows. At the same time, evolving regulatory expectations and reimbursement frameworks are shaping how assays translate from the bench to bedside.

This introduction frames targeted sequencing as a dynamic, modular platform space where instruments, consumables, and software integrate into end-to-end solutions. It underscores the importance of interoperability and workflow optimization while highlighting the strategic choices that organizations face when selecting platforms, designing panels, and building analytic pipelines. The rest of the summary elaborates on technological inflection points, external policy impacts, segmentation nuances, regional performance differentials, and actionable recommendations for leaders seeking to capture value from this rapidly maturing domain.

How chemistry advances, scalable instrument architectures, and maturing bioinformatics are jointly redefining clinical and research utility across targeted sequencing workflows

The past several years have produced transformative shifts that reshape how stakeholders develop, deploy, and monetize targeted sequencing solutions. First, chemistry and library-preparation innovations have compressed turnaround times and improved on-target efficiency, enabling diagnostics laboratories to deliver faster, higher-confidence results. These technical gains have been paralleled by instrument architectures that scale from benchtop systems for decentralized testing to high-throughput platforms for centralized sequencing hubs, thereby expanding the addressable use-cases from single-patient diagnostics to large-scale cohort studies.

Concurrently, bioinformatics has moved from a supporting role to a strategic capability. Sophisticated variant callers, standardized pipelines, and explainable annotation layers now drive clinical-grade interpretations and reduce time-to-decision for clinicians and researchers. This maturation of software and services increases the value capture for vendors offering integrated analytics and paves the way for subscription or outcome-linked commercial models.

Market dynamics also reflect a shift toward modular ecosystems where reagents, kits, and third-party analytical tools coexist. Organizations increasingly prefer flexible platform strategies that decouple instrument procurement from reagent sourcing to avoid vendor lock-in and maintain agility in assay design. At the same time, partnerships between sequencing providers, reagent developers, and bioinformatics firms have intensified, facilitating bundled solutions that accelerate adoption in hospital laboratories and research centers.

Regulatory and reimbursement landscapes are further influencing product design and commercial rollout. Regulatory frameworks that emphasize clinical validation and traceability have prompted providers to strengthen quality systems, produce robust validation datasets, and engage earlier with regulators. Meanwhile, payers are beginning to demand stronger evidence of clinical utility and cost-effectiveness for broad deployment, encouraging developers to align evidence-generation strategies with reimbursement needs. Taken together, these shifts are redefining the competitive logic of the field and guiding where capital and talent will concentrate in the near term.

How 2025 tariff adjustments catalyzed supply-chain resilience, localization investments, and strategic sourcing shifts across the targeted sequencing ecosystem

The cumulative impact of the United States tariff adjustments implemented in 2025 has introduced measurable friction across the targeted sequencing value chain, influencing sourcing strategies, pricing dynamics, and supply continuity. Tariff-related cost pressures have affected both capital equipment and consumables, elevating landed costs for instruments and reagents imported into the United States. As a result, providers and end users have recalibrated procurement plans and accelerated vendor diversification to maintain operational budgets and program timelines.

In response to these trade measures, many suppliers intensified efforts to localize production, either by shifting key manufacturing steps to domestic facilities or by qualifying alternative suppliers in tariff-exempt jurisdictions. These adjustments reduced immediate exposure to import levies but required short-term capital investments and supply-chain revalidation. For some reagent and kit manufacturers, the need to requalify manufacturing sites and to replicate quality-control processes introduced incremental lead times and batch equivalency assessments that impacted product availability.

Beyond manufacturing shifts, the tariff environment amplified the strategic importance of supply-chain resilience. Organizations placed greater emphasis on inventory buffering, multi-sourcing contracts, and contractual protection clauses to mitigate the risk of sudden cost escalation. Moreover, procurement teams increasingly incorporated total landed cost analyses that accounted for duties, compliance overhead, and potential delays. These practices favored suppliers with geographically distributed manufacturing footprints and robust logistics capabilities.

Finally, the tariff adjustments have influenced collaborative and commercial behaviors. Strategic partnerships and co-investment models gained traction as vendors and service providers sought to share localization costs and to secure preferential access to critical components. Concurrently, some academic and research institutions explored reagent sharing consortia and centralized procurement frameworks to preserve research continuity. While tariffs introduced near-term cost and operational complexity, they also catalyzed supply-chain modernization and encouraged stakeholders to strengthen long-term resilience strategies.

Deep segmentation-driven insights linking product architectures, platform choices, end-user priorities, and application requirements to strategic decision pathways

Segmentation analysis reveals distinct technology stacks, user needs, and commercial pressures that should guide portfolio and go-to-market strategies. Based on product type, the landscape separates into Instruments, Reagents & Kits, and Software & Services. Instruments span benchtop sequencers suited for decentralized, lower-throughput testing and high-throughput sequencers designed for central laboratories and large-scale studies. Reagents and kits include amplicon-based, hybridization-based, and molecular inversion probe formats, each optimized for different target breadths, sample types, and sensitivity requirements. Software and services cover bioinformatics services and data analysis software, reflecting the growing demand for interpretation, pipeline validation, and regulatory-grade reporting.

Platform segmentation further clarifies technical trade-offs and application fit. Amplicon sequencing workflows, including multiplex PCR and unique molecular identifier (UMI)-based approaches, deliver high sensitivity for focused panels and low-input samples. Hybrid capture strategies, realized through baits-based and probe-based capture formats, enable broader panel coverage and improved uniformity for complex targets. Molecular inversion probes are tailored for highly multiplexed detection and include probes optimized for copy-number variation analysis and single-nucleotide polymorphism detection, offering cost-efficient scalability for targeted discovery and genotyping projects.

End-user segmentation highlights differing operational imperatives and procurement patterns. Academic and research institutes, including both private research labs and public research labs, prioritize methodological flexibility, publication-grade data quality, and grant-driven timelines. Hospitals and diagnostic centers, encompassing point-of-care laboratories and reference laboratories, emphasize regulatory compliance, reproducibility, and rapid clinical turnaround. Pharmaceutical and biotechnology companies, including clinical research organizations and drug discovery units, focus on assay robustness, scalability for clinical trials, and integration with biomarker and companion diagnostic programs.

Application segmentation underscores the range of use-cases that drive platform choice and partner selection. Biomarker discovery applications, spanning pharmacogenomic and predictive biomarkers, require deep coverage and high annotation fidelity. Genetic disease workflows, including prenatal testing and rare disease diagnosis, demand validated assays with low false-negative rates and clear clinical reporting. Infectious disease applications-antibiotic resistance testing and pathogen detection-prioritize rapid, sensitive assays that accommodate diverse sample matrices. Oncology applications across diagnostics, prognostics, and theranostics require flexible panel design, compatibility with liquid biopsies, and analytical pipelines that support clinical decision-making. Understanding these segmentation interdependencies enables stakeholders to align product development, commercialization, and service offerings with clearly defined technical and clinical requirements.

Comparative regional dynamics and strategic imperatives across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping adoption and commercialization

Regional dynamics vary substantially, shaping technology adoption, regulatory strategies, and partnership models across the Americas, Europe, Middle East & Africa, and Asia-Pacific. In the Americas, investment in diagnostic infrastructure, coupled with a large clinical research base, encourages rapid uptake of high-throughput platforms and integrated bioinformatics solutions that support translational research and centralized testing networks. Stakeholders in this region prioritize regulatory alignment with local authorities, clinical validation, and evidence generation to support clinical adoption and payer engagement.

Within Europe, Middle East & Africa, diverse regulatory regimes and varying healthcare funding models create differentiated adoption pathways. Western European markets tend to emphasize interoperability, standardized data reporting, and quality systems, while emerging markets in the region focus on access, capacity building, and cost-effective workflows. Collaborative public-private initiatives and regional reference laboratory networks play an outsized role in scaling targeted sequencing for public health and oncology programs.

Asia-Pacific demonstrates rapid capacity expansion driven by public investment, large patient populations, and ambitious precision-medicine initiatives. Several countries are investing heavily in localized manufacturing, domestic R&D, and national genomics programs, which accelerates demand for both benchtop systems for decentralized testing and high-throughput platforms for population-scale studies. Across the region, partnerships between global vendors and local service providers or manufacturers help tailor offerings to regulatory expectations and price sensitivity while advancing technology transfer and workforce development.

Across all regions, cross-border collaboration, data harmonization efforts, and regulatory convergence are emerging themes that support multinational clinical studies and diagnostic rollouts. Regional infrastructure maturity, payer policies, and local manufacturing capabilities continue to shape supplier selection and commercial strategies, underscoring the need for geographically nuanced go-to-market plans.

How specialization in instruments, reagents, and bioinformatics combined with partnerships and service models determines sustainable competitive positioning

Company-level trends reflect a competitive landscape where specialization, integration, and service differentiation determine positioning. Vendors focused on instrument innovation emphasize throughput, automation, and sample-to-answer workflows that reduce hands-on time and enable decentralized testing. Conversely, reagent and kit providers concentrate on assay robustness, lot-to-lot consistency, and ease of integration with multiple platforms to maximize addressable use cases.

Software and service providers are increasingly differentiating on clinical interpretive capabilities, regulatory readiness, and the ability to deliver validated pipelines that meet laboratory accreditation requirements. Managed services, cloud-enabled analytics, and certified reference databases have become important value levers for organizations seeking to outsource complex analytics or to accelerate clinical deployment. Strategic alliances between instrument manufacturers and bioinformatics firms have proliferated to offer bundled solutions that shorten validation timelines and improve customer retention.

Emerging companies and specialized service providers play a crucial role in niche innovation, developing novel chemistries, bespoke capture probes, and highly optimized panels for hard-to-sequence targets. These smaller entities often collaborate with larger partners for scale-up and distribution while retaining agility in product development and customer engagement. Meanwhile, contract research organizations and clinical CROs expand their offerings to include targeted sequencing assay development and sample management services, responding to sponsors' demand for end-to-end trial-ready workflows.

Overall, successful companies combine technical excellence with robust quality systems, clear regulatory strategies, and customer-centric commercialization models. Firms that invest in evidence generation, interoperability, and flexible commercial structures are better positioned to capture long-term value as clinical and research adoption continues to mature.

Practical strategic priorities for leaders to enhance interoperability, regulatory readiness, supply-chain resilience, and evidence-driven commercialization

Industry leaders should pursue a coordinated set of strategic actions to strengthen resilience, accelerate adoption, and capture higher-value opportunities. First, prioritize platform interoperability and open standards so that customers can integrate instruments, reagents, and analytics with minimal friction; this reduces buyer resistance and expands the addressable user base. Second, invest in regulatory and clinical-evidence capabilities early in the product lifecycle to shorten time-to-clinical utility and to support reimbursement discussions.

Third, diversify manufacturing and sourcing footprints to mitigate tariff and geopolitical risk while ensuring consistent supply for critical consumables. Coupled with this, develop flexible commercial models-such as reagent-as-a-service, subscription analytics, or outcome-linked agreements-that align vendor incentives with customers' operational and fiscal objectives. Fourth, strengthen partnerships with clinical laboratories, academic consortia, and pharmaceutical sponsors to co-develop panels and generate real-world evidence that demonstrates utility across diagnostic and therapeutic workflows.

Fifth, prioritize talent development in bioinformatics and assay validation to maintain high analytical standards and to accelerate time-to-insight for customers. Sixth, implement rigorous quality-management systems and documentation practices to streamline regulatory submissions and to facilitate multi-jurisdictional approvals. Finally, adopt a data governance posture that emphasizes interoperability, patient privacy, and secure cloud architectures to enable scalable analytics while preserving compliance.

Collectively, these actions create a durable competitive foundation by aligning product roadmaps with customer needs, regulatory realities, and operational constraints, enabling organizations to convert technical capabilities into sustainable commercial outcomes.

A mixed-methods research framework combining stakeholder interviews, technical literature synthesis, and regulatory review to ensure context-aware actionable insights

This research synthesizes primary and secondary inputs to generate a comprehensive assessment of targeted sequencing dynamics, drawing on structured interviews, technical validation reviews, and cross-regional policy analysis. Primary qualitative interviews were conducted with laboratory directors, assay developers, procurement leaders, and regulatory specialists to capture operational pain points, adoption drivers, and evidence-generation strategies. These conversations informed the interpretation of technical trade-offs across platform architectures and guided recommendations for commercialization and product development.

Secondary inputs included peer-reviewed literature, regulatory guidance documents, clinical-pathway analyses, and published technical performance studies that describe assay sensitivity, specificity, and workflow constraints. The analysis also leveraged publicly available clinical trial registries, patent filings, and conference proceedings to map innovation trajectories and to identify emerging chemistries and analytic approaches. Comparative policy reviews assessed regional regulatory expectations, quality standards, and reimbursement frameworks that influence clinical deployment.

Analytical approaches combined qualitative synthesis with cross-sectional benchmarking of technology attributes, user needs, and regional enablers. Validation steps included triangulating interview insights with technical performance claims and regulatory precedents, ensuring the conclusions reflect real-world implementation considerations. Limitations of the research are acknowledged where proprietary performance data or confidential commercial agreements restrict visibility; where appropriate, recommendations emphasize adaptable strategies that perform under varying evidentiary and regulatory conditions.

This mixed-methods approach produces actionable, context-aware insights intended to support decision-making across R&D planning, commercial strategy, and operational risk management.

Synthesis of strategic imperatives and operational guidance to translate targeted sequencing advancements into durable clinical and commercial impact

In conclusion, targeted sequencing occupies a strategic intersection between technological capability and clinical need, offering focused genomic interrogation that supports diagnostics, therapeutics, and public health applications. Advances in chemistry, instrumentation, and bioinformatics have expanded the technique's utility while driving new commercial models that couple assays with integrated analytics. At the same time, external forces-including regulatory expectations, payer scrutiny, and trade policy-shape how products move from development into routine use.

Stakeholders that align product development with rigorous evidence-generation, adopt supply-chain diversification, and prioritize interoperability will be best positioned to capture sustained value. Regional nuances require tailored strategies: centralized high-throughput approaches work well where regulatory and reimbursement systems support scale, while benchtop and decentralized solutions address demand for rapid, point-of-care decision-making. Finally, companies that combine technical excellence with thoughtful commercial and regulatory execution will find the greatest opportunities to differentiate and to secure long-term partnerships with diagnostic laboratories, healthcare systems, and pharmaceutical sponsors.

This executive summary provides a strategic foundation for leaders seeking to prioritize investments, design collaborative programs, and navigate operational risks in the evolving targeted sequencing landscape. The recommendations and insights herein are intended to support disciplined decision-making and to accelerate the translation of targeted sequencing innovation into measurable clinical and research impact.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Targeted Sequencing Market, by Product Type

  • 8.1. Instruments
    • 8.1.1. Benchtop Sequencers
    • 8.1.2. High-Throughput Sequencers
  • 8.2. Reagents & Kits
    • 8.2.1. Amplicon-Based Kits
    • 8.2.2. Hybridization-Based Kits
    • 8.2.3. MIP-Based Kits
  • 8.3. Software & Services
    • 8.3.1. Bioinformatics Services
    • 8.3.2. Data Analysis Software

9. Targeted Sequencing Market, by Platform

  • 9.1. Amplicon Sequencing
    • 9.1.1. Multiplex PCR
    • 9.1.2. UMI-Based Sequencing
  • 9.2. Hybrid Capture
    • 9.2.1. Baits-Based Capture
    • 9.2.2. Probe-Based Capture
  • 9.3. Molecular Inversion Probes
    • 9.3.1. MIP Probes For CNV Analysis
    • 9.3.2. MIP Probes For SNP Detection

10. Targeted Sequencing Market, by End User

  • 10.1. Academic & Research Institutes
  • 10.2. Hospitals & Diagnostic Centers
    • 10.2.1. Point-of-Care Laboratories
    • 10.2.2. Reference Laboratories
  • 10.3. Pharmaceutical & Biotechnology Companies
    • 10.3.1. Clinical Research Organizations
    • 10.3.2. Drug Discovery Units

11. Targeted Sequencing Market, by Application

  • 11.1. Biomarker Discovery
    • 11.1.1. Pharmacogenomic Biomarkers
    • 11.1.2. Predictive Biomarkers
  • 11.2. Genetic Diseases
    • 11.2.1. Prenatal Testing
    • 11.2.2. Rare Disease Diagnosis
  • 11.3. Infectious Diseases
    • 11.3.1. Antibiotic Resistance Testing
    • 11.3.2. Pathogen Detection
  • 11.4. Oncology
    • 11.4.1. Diagnostics
    • 11.4.2. Prognostics
    • 11.4.3. Theranostics

12. Targeted Sequencing Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Targeted Sequencing Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Targeted Sequencing Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Targeted Sequencing Market

16. China Targeted Sequencing Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. 10x Genomics, Inc.
  • 17.6. A-Alpha Bio, Inc.
  • 17.7. Agilent Technologies, Inc.
  • 17.8. Azenta Life Sciences
  • 17.9. BGI Genomics Co., Ltd.
  • 17.10. Bio-Rad Laboratories, Inc.
  • 17.11. CD Genomics
  • 17.12. DH Life Sciences, LLC
  • 17.13. Element Biosciences
  • 17.14. F. Hoffmann-La Roche Ltd.
  • 17.15. Illumina, Inc.
  • 17.16. LGC Limited
  • 17.17. Macrogen, Inc.
  • 17.18. MGI Tech Co., Ltd.
  • 17.19. Oxford Nanopore Technologies PLC
  • 17.20. Pacific Biosciences of California, Inc.
  • 17.21. Paragon Genomics, Inc.
  • 17.22. PerkinElmer, Inc.
  • 17.23. Psomagen, Inc.
  • 17.24. QIAGEN N.V.
  • 17.25. Singular Genomics Systems, Inc.
  • 17.26. Takara Bio Inc.
  • 17.27. Tecan Trading AG
  • 17.28. Thermo Fisher Scientific Inc.
  • 17.29. Twist Bioscience Corporation

LIST OF FIGURES

  • FIGURE 1. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL TARGETED SEQUENCING MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL TARGETED SEQUENCING MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL TARGETED SEQUENCING MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BENCHTOP SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HIGH-THROUGHPUT SEQUENCERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON-BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRIDIZATION-BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP-BASED KITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOINFORMATICS SERVICES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DATA ANALYSIS SOFTWARE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MULTIPLEX PCR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY UMI-BASED SEQUENCING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BAITS-BASED CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROBE-BASED CAPTURE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR CNV ANALYSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 66. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY MIP PROBES FOR SNP DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 67. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 68. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 69. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 70. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 71. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 72. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 73. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 74. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 75. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 76. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 77. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY POINT-OF-CARE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 79. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 80. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REFERENCE LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 81. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 82. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 83. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 85. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 86. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 87. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY CLINICAL RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 88. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 89. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 90. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DRUG DISCOVERY UNITS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 91. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 92. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 93. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 94. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 95. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 96. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 97. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 98. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PHARMACOGENOMIC BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 99. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 100. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 101. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PREDICTIVE BIOMARKERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 103. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 104. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 105. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 106. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PRENATAL TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 110. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 111. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY RARE DISEASE DIAGNOSIS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 112. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 116. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 117. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 118. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ANTIBIOTIC RESISTANCE TESTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 119. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 120. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 121. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PATHOGEN DETECTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 122. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 123. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 124. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 125. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 126. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 127. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 128. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY DIAGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 129. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 130. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 131. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY PROGNOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 132. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 133. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 134. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY THERANOSTICS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 135. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 136. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 137. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 138. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 139. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 140. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 141. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 142. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 143. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 144. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 145. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 146. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 147. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 148. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 149. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 150. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 151. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 152. AMERICAS TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 153. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 154. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 156. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 157. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 158. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 159. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 160. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 161. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 162. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 163. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 164. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 165. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 166. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 167. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 168. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 169. NORTH AMERICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 170. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 171. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 172. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 173. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 174. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 175. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 176. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 177. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 178. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 179. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 180. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 181. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 182. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 183. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 184. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 185. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 186. LATIN AMERICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 187. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 188. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 189. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 190. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 191. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 192. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 193. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 194. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 195. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 196. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 197. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 198. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 204. EUROPE TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 205. EUROPE TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 206. EUROPE TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 207. EUROPE TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 208. EUROPE TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 209. EUROPE TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 210. EUROPE TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 211. EUROPE TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 212. EUROPE TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 213. EUROPE TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 214. EUROPE TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 215. EUROPE TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 216. EUROPE TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 217. EUROPE TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 218. EUROPE TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 219. EUROPE TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 220. EUROPE TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 221. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 222. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 223. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 224. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 225. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 226. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 227. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 228. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 229. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 230. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 231. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 232. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 233. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 234. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 235. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 236. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 237. MIDDLE EAST TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 238. AFRICA TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 239. AFRICA TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 240. AFRICA TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 241. AFRICA TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 242. AFRICA TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 243. AFRICA TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 244. AFRICA TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 245. AFRICA TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 246. AFRICA TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 247. AFRICA TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 248. AFRICA TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 249. AFRICA TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 250. AFRICA TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 251. AFRICA TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 252. AFRICA TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 253. AFRICA TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 254. AFRICA TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 255. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 256. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 257. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 258. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 259. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 260. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 261. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 262. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 263. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 264. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 265. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 266. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 267. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 268. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 269. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 270. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 271. ASIA-PACIFIC TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 272. GLOBAL TARGETED SEQUENCING MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 273. ASEAN TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 274. ASEAN TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 275. ASEAN TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 276. ASEAN TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 277. ASEAN TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 278. ASEAN TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 279. ASEAN TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 280. ASEAN TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 281. ASEAN TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 282. ASEAN TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 283. ASEAN TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 284. ASEAN TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 285. ASEAN TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 286. ASEAN TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 287. ASEAN TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 288. ASEAN TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 289. ASEAN TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 290. GCC TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 291. GCC TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 292. GCC TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 293. GCC TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 294. GCC TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 295. GCC TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 296. GCC TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 297. GCC TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 298. GCC TARGETED SEQUENCING MARKET SIZE, BY MOLECULAR INVERSION PROBES, 2018-2032 (USD MILLION)
  • TABLE 299. GCC TARGETED SEQUENCING MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 300. GCC TARGETED SEQUENCING MARKET SIZE, BY HOSPITALS & DIAGNOSTIC CENTERS, 2018-2032 (USD MILLION)
  • TABLE 301. GCC TARGETED SEQUENCING MARKET SIZE, BY PHARMACEUTICAL & BIOTECHNOLOGY COMPANIES, 2018-2032 (USD MILLION)
  • TABLE 302. GCC TARGETED SEQUENCING MARKET SIZE, BY APPLICATION, 2018-2032 (USD MILLION)
  • TABLE 303. GCC TARGETED SEQUENCING MARKET SIZE, BY BIOMARKER DISCOVERY, 2018-2032 (USD MILLION)
  • TABLE 304. GCC TARGETED SEQUENCING MARKET SIZE, BY GENETIC DISEASES, 2018-2032 (USD MILLION)
  • TABLE 305. GCC TARGETED SEQUENCING MARKET SIZE, BY INFECTIOUS DISEASES, 2018-2032 (USD MILLION)
  • TABLE 306. GCC TARGETED SEQUENCING MARKET SIZE, BY ONCOLOGY, 2018-2032 (USD MILLION)
  • TABLE 307. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 308. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY PRODUCT TYPE, 2018-2032 (USD MILLION)
  • TABLE 309. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY INSTRUMENTS, 2018-2032 (USD MILLION)
  • TABLE 310. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY REAGENTS & KITS, 2018-2032 (USD MILLION)
  • TABLE 311. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY SOFTWARE & SERVICES, 2018-2032 (USD MILLION)
  • TABLE 312. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY PLATFORM, 2018-2032 (USD MILLION)
  • TABLE 313. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY AMPLICON SEQUENCING, 2018-2032 (USD MILLION)
  • TABLE 314. EUROPEAN UNION TARGETED SEQUENCING MARKET SIZE, BY HYBRID CAPTURE, 2018-2032 (USD MILLION)
  • TABLE 315. EURO